Maureen Newman is a researcher by trade, and brings her knowledge of the lab to her reporting. Currently, she is serving as a PhD student at University of Rochester, and working towards a career of research in biomaterials for drug delivery and regenerative medicine. She is an integral part of Dr. Danielle Benoit’s laboratory, where she is investigating bone-homing therapeutics for osteoporosis treatment.
Individuals with human immunodeficiency virus (HIV) seem to have higher rates of lymphoma development, especially grade B-non Hodgkin lymphomas (NHL). However, these lymphomas, which are also the most common types ... Read more
Autologous stem cell transplantation (SCT) is one treatment procedure for multiple myeloma, non-Hodgkin lymphoma, and Hodgkin lymphoma that has shown clinical success. However, there is room for improvement in the ... Read more
An open-label clinical trial for non-Hodgkin B-cell lymphoma tested fostamatinib tablets in 81 patients with a lymphoid malignancy. Results indicate that fostamatinib has some level of efficacy in patients with diffuse ... Read more
A completed Phase 2 clinical trial in relapsed or refractory systemic Anaplastic Large Cell Lymphoma (ALCL) demonstrated that the experimental drug UCN-01 (7-hydroxystaurosporine) produced a complete clinical response in 18% ... Read more
Researchers at University Hospital of the Ludwig-Maximilians-University Munich are working towards creating a prognostic model for lymphoma patients based on the presence of genetic mutations in patient DNA. The model, ... Read more
An ongoing clinical trial from University College London in collaboration with Christie Hospital NHS Foundation Trust found that patients with Stage IA or Stage IIA Hodgkin Lymphoma may be adequately treated ... Read more